Shao Ming Lu

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor
    Matthew J Bellizzi
    Department of Neurology, Child Neurology Division, Center for Aging and Developmental Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Invest 115:3185-92. 2005
  2. ncbi request reprint The phospholipid mediator platelet-activating factor mediates striatal synaptic facilitation
    Shao Ming Lu
    Center for Aging and Developmental Biology, Aab Biomedical Institute, University of Rochester Medical Center, Box 645, 601, Elmwood Avenue, Rochester, NY 14642, USA
    J Neuroimmune Pharmacol 2:194-201. 2007
  3. pmc HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells
    Shao Ming Lu
    Center for Neural Development and Disease, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
    PLoS ONE 6:e23915. 2011
  4. pmc The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders
    Daniel F Marker
    Centers for Neural Development and Disease, University of Rochester, Rochester, New York 14642, USA
    J Neurosci 33:9998-10010. 2013
  5. pmc LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein
    Daniel F Marker
    Center for Neural Development and Disease, Department of Neurology, Child Neurology Division, University of Rochester, Rochester, NY, USA
    J Neuroinflammation 9:261. 2012
  6. ncbi request reprint Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease
    Matthew J Bellizzi
    Department of Neurology Child Neurology Division, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Neuroimmune Pharmacol 1:20-31. 2006
  7. pmc NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity
    ALISON O'MAHONY
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, San Francisco, CA 94141, USA
    Mol Cell Biol 26:7283-98. 2006

Collaborators

Detail Information

Publications7

  1. pmc Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor
    Matthew J Bellizzi
    Department of Neurology, Child Neurology Division, Center for Aging and Developmental Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Invest 115:3185-92. 2005
    ..Furthermore, preconditioning may represent a novel therapeutic strategy for preventing excitotoxic injury while preserving physiologic plasticity...
  2. ncbi request reprint The phospholipid mediator platelet-activating factor mediates striatal synaptic facilitation
    Shao Ming Lu
    Center for Aging and Developmental Biology, Aab Biomedical Institute, University of Rochester Medical Center, Box 645, 601, Elmwood Avenue, Rochester, NY 14642, USA
    J Neuroimmune Pharmacol 2:194-201. 2007
    ..Thus, the relative concentration and temporal pattern of PAF expression at glutamatergic synapses may govern whether it acts in a physiologic or pathophysiologic manner during striatal neurotransmission...
  3. pmc HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells
    Shao Ming Lu
    Center for Neural Development and Disease, University of Rochester School of Medicine and Dentistry, Rochester, New York, United States of America
    PLoS ONE 6:e23915. 2011
    ....
  4. pmc The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders
    Daniel F Marker
    Centers for Neural Development and Disease, University of Rochester, Rochester, New York 14642, USA
    J Neurosci 33:9998-10010. 2013
    ..In conclusion, these data provide compelling in vitro and in vivo evidence to investigate the utility of URMC-099 in other models of HAND with the goal of advancement to an adjunctive therapeutic agent...
  5. pmc LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein
    Daniel F Marker
    Center for Neural Development and Disease, Department of Neurology, Child Neurology Division, University of Rochester, Rochester, NY, USA
    J Neuroinflammation 9:261. 2012
    ....
  6. ncbi request reprint Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease
    Matthew J Bellizzi
    Department of Neurology Child Neurology Division, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Neuroimmune Pharmacol 1:20-31. 2006
    ..Whereas patients with HAD beginning antiretroviral therapy have shown reversal of neurologic symptoms that is unique for patients with chronic neurodegenerative conditions, we propose that the potential for such reversal is not unique...
  7. pmc NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity
    ALISON O'MAHONY
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, San Francisco, CA 94141, USA
    Mol Cell Biol 26:7283-98. 2006
    ..These findings suggest that NF-kappaB/Rel transcription factors act as pivotal regulators of activity-dependent inhibitory and excitatory neuronal function regulating synaptic plasticity and memory...